Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution
[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Shin Y.A., Jin H., Lee Y., Shin H.B., Son Y.J
--- FAQ: GHK-Cu and the FDA Category 2 Removal Is GHK-Cu now FDA-approved
About BPC-157 Peptide and TB-500 BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide derived from a protein found in human gastric juice 2
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Early trial data suggest retatrutide could lead to greater average weight loss than tirzepatide, but its long-term safety, side effects, and real-world tolerability are still being studied
US$ 20.38
US$ 25.78
US$ 27.18
